It has been shown recently that metformin, the indirect mTOR-kinase inhibitor, significantly increases medium (by 37.8%) and maximum (by 10.3%) life span of SHR mice (Anisimov et al., 2008). We obtained fibroblasts from skin of 11-, 16-, 19- and 23-months-old SHR mice treated with metformin since the third and ninth day of life. We studied markers of cellular senescence in these fibroblasts. Significant differences were observed between the average number of senescence-associated heterochromatic foci (SAHF), the average of area nuclei and fluorescence intensity of nucleus after staining for gamma-H2AX in control and experimental animals. Also, we showed that metformin prevented the accumulation of fibroblasts with large area of nuclei; high activity of senescence-associated beta-galactosidase (SA-beta-gal), and high fluorescence intensity after staining for gamma-H2AX. It appears that accumulation of large quantity of senescence markers within a cell triggers it to enter the aging process. It appears that the increase of "old" cell population above the threshold disrupts the normal function of certain tissues, organs, and finally, the whole organism. It appears that metformin delays the "old" cells accumulation and prolongs the organism youth.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.
Cancer Biol Ther
December 2024
Innovative Drug R&D, Pre-clinical Development and Translational Medicine, Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai, China.
Anti-CTLA-4 and anti-PD-1/PD-L1 antibodies have significantly revolutionized cancer immunotherapy. However, the persistent challenge of low patient response rates necessitates novel approaches to overcome immune tolerance. Targeting immunostimulatory signaling may have a better chance of success for its ability to enhance effector T cell (Teff) function and expansion for antitumor immunity.
View Article and Find Full Text PDFMutant-selective AKT inhibition through lysine targeting and neo-zinc chelation.
Nature
January 2025
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
Somatic alterations in the oncogenic kinase AKT1 have been identified in a broad spectrum of solid tumours. The most common AKT1 alteration replaces Glu17 with Lys (E17K) in the regulatory pleckstrin homology domain, resulting in constitutive membrane localization and activation of oncogenic signalling. In clinical studies, pan-AKT inhibitors have been found to cause dose-limiting hyperglycaemia, which has motivated the search for mutant-selective inhibitors.
View Article and Find Full Text PDFArticle Synopsis
- Infants have an immature immune system and narrower airways, making them more vulnerable to severe respiratory syncytial virus (RSV) infections.
- A study by Zhao et al. found that airway cells from children are more susceptible to damage from RSV than those from adults, due to poor STAT3 activation.
- Enhancing STAT3 activation and using apoptosis inhibitors in neonatal mice showed promise in reducing virus spread, indicating potential therapeutic strategies for treating RSV in infants.
Sirtuin 7 ameliorates cuproptosis, myocardial remodeling and heart dysfunction in hypertension through the modulation of YAP/ATP7A signaling.
Apoptosis
December 2024
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.
Myocardial fibrosis is a typical pathological manifestation of hypertension. However, the exact role of sirtuin 7 (SIRT7) in myocardial remodeling remains largely unclear. Here, spontaneously hypertensive rats (SHRs) and angiotensin (Ang) II-induced hypertensive mice were pretreated with recombinant adeno-associated virus (rAAV)-SIRT7, copper chelator tetrathiomolybdate (TTM) or copper ionophore elesclomol, respectively.
View Article and Find Full Text PDFSafety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies.
Alzheimers Res Ther
October 2024
Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Article Synopsis
- SHR-1707 is a novel monoclonal antibody designed to target Aβ, aiming to reduce plaque formation in potential Alzheimer's disease treatment; preclinical tests in mice have shown promising results in decreasing Aβ deposits.* -
- Two phase 1 clinical trials were conducted to assess SHR-1707 in healthy adults in China and Australia, focusing on safety, tolerability, and how the drug behaves in the body (pharmacokinetics and pharmacodynamics) after a single intravenous dose.* -
- Results indicated that SHR-1707 was generally well-tolerated with mostly mild adverse effects reported; the drug showed a dose-dependent increase in plasma Aβ levels, with similar safety and body response profiles observed in both younger and
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!